pixlbio

Pixlbio is a biotechnology company formed in 2025 through the merger of DefiniGEN and Phenaros. The company operates an integrated platform that combines high-fidelity, human iPSC-derived cell models with next-generation computational phenomics and AI-driven analytics. By utilizing proprietary differentiation protocols to generate human-relevant models—such as hepatocytes and organoids—alongside high-content imaging and automated cell painting, pixlbio decodes how cells behave and respond to stimuli. This integrated approach aims to bridge biology and machine intelligence, enabling researchers to conduct more precise and predictive drug discovery experiments.

The company’s platform provides essential capabilities for drug development and safety assessment, helping customers overcome challenges in toxicology, mechanism-of-action studies, and efficacy testing. Pixlbio supports academic and commercial partners by offering flexible study designs and curated data packages that facilitate reproducible biological insights. The company is actively involved in industry-leading regulatory research, including participation in a landmark FDA–3Rs Collaborative cross-platform study for drug-induced liver injury (DILI) that was accepted into the FDA's ISTAND qualification program. Through these efforts, pixlbio continues the scientific legacy of its predecessor, DefiniGEN, while advancing the use of human-centric new approach methodologies in drug discovery.